Drug Profile
AV 115
Alternative Names: AV-115Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator AviMed Pharmaceuticals
- Developer AviMed Pharmaceuticals; Concordia University; Marquette University
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Schizophrenia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Schizophrenia in USA